Acyclonucleoside Iron Chelators of 1-(2-Hydroxyethoxy)methyl-2-alkyl-3-hydroxy-4-pyridinones: Potential Oral Iron Chelation Therapeutics

Nucleosides, Nucleotides and Nucleic Acids

Volumn 23, Issue 3, 2004, Pages 599-611

  Liu, Gang ^a   Men, Ping ^a   Kenner, Gerry H ^a   Miller, Scott C ^a   Bruenger, Fred W ^a  

^a UNIVERSITY OF UTAH   (United States)

Author keywords

Acyclonucleoside; Desferrioxamine; Iron chelators; Pyridinones; Therapeutics

Indexed keywords

ACYCLIC NUCLEOSIDE; DEFEROXAMINE; FERRITIN; IRON CHELATING AGENT; OCTANOL; PYRIDONE DERIVATIVE; RIBONUCLEOSIDE;

ARTICLE; CHELATION THERAPY; CHEMICAL REACTION; CRYSTAL STRUCTURE; DRUG SYNTHESIS; IRON CHELATION; TITRIMETRY; X RAY CRYSTALLOGRAPHY;

CHELATION THERAPY; CRYSTALLOGRAPHY, X-RAY; HUMANS; IRON; IRON CHELATING AGENTS; IRON OVERLOAD; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PYRIDONES;

EID: 1942519406     PISSN: 15257770     EISSN: None     Source Type: Journal    
DOI: 10.1081/NCN-120030718     Document Type: Article

References (30)

1. Martell, A.E.; Motekaitis, R.J.; Sun, Y.; Ma, R.; Welch, M.J.; Pajeau, T. New chelating agents suitable for the treatment of iron overload. Inorg. Chim. Acta 1999, 291 (1-2), 238-246.
2. Gabutti, V.; Piga, A. Results of long-term iron-chelating therapy. Acta Haematol. 1996, 95 (1), 26-36.
3. Hershko, C.; Konijn, A.M.; Link, G. Iron chelators for thalassaemia. Br. J. Haematol. 1998, 101 (3), 399-406.
4. Olivieri, N.F.; Brittenham, G.M. Iron-chelating therapy and the treatment of thalassemia. Blood 1997, 89 (3), 739-761.
5. Hershko, C. Control of disease by selective iron depletion: a novel therapeutic strategy utilizing iron chelators. Bailliere's Clin. Haematol. 1994, 7 (4), 965-1000.
6. Kontoghiorghes, G.J.; Weinberg, E.D. Iron: mammalian defense systems, mechanisms of disease, and chelation therapy approaches. Blood Rev. 1995, 9 (1), 33-45.
7. Richardson, D.R.; Ponka, P. Development of iron chelators to treat iron overload disease and their use as experimental tools to probe intracellular iron metabolism. Am. J. Hematol. 1998, 58 (4), 299-305.
8. Porter, J.B.; Hider, R.C.; Huehns, E.R. Update on the hydroxypyridinone oral iron-chelating agents. Semin. Hematol. 1990, 27 (2), 95-100.
9. Liu, G.; Bruenger, F.W.; Barrios, A.M.; Miller, S.C. Synthesis of 2-alkyl-3-hydroxy-4-pyridinone-ribonucleosides, potential oral iron chelators. Nucleosides Nucleotides 1995, 14 (9&10), 1901-1904.
10. Liu, G.; Bruenger, F.W.; Miller, S.C.; Arif, A.M. Molecular structure and biological and pharmacological properties of 3-hydroxy-2-methyl-1-(β -D-ribofuranosyl or pyranosyl)-4-pyridinone: potential iron overload drugs for oral administration. Bioorg. Med. Chem. Lett. 1998, 8 (21), 3077-3080.
11. Schaeffer, H.J.; Gurwara, S.; Vince, R.; Bittner, S. Novel substrate of adenosine deaminase. J. Med. Chem. 1971, 14 (4), 367-369.
12. Liu, G.; Miller, S.C.; Bruenger, F.W. Efficient synthesis of n-[(2-hydroxyethoxy)methyl]-2-alkyl-3-hydroxy-4-pyridinone by a modified Hilbert-Johnson reaction. Synth. Commun. 1996, 26 (14), 2681-2686.
13. Dobbin, P.S.; Hider, R.C.; Hall, A.D.; Taylor, P.D.; Sarpong, P.; Porter, J.B.; Xiao, G.; van der Helm, D. Synthesis, physicochemical properties, and biological evaluation of N-substituted 2-alkyl-3-hydroxy-4(1H)-pyridinones: orally active iron chelators with clinical potential. J. Med. Chem. 1993, 36 (17), 2448-2458.
14. Robins, M.J.; Hatfield, P.W. Nucleic acid related compounds. 37. Convenient and high-yield syntheses of N-[(2-hydroxyethoxy)methyl] heterocycles as "acyclic nucleoside" analogues. Can. J. Chem. 1982, 60 (5), 547-553.
15. Miyasaka, T.; Tanaka, H.; Baba, M.; Hayakawa, H.; Walker, R.T.; Balzarini, J.; De Clercq, E. A novel lead for specific anti-HIV-1 agents: 1-[(2-hydroxyethoxy)-methyl]-6-(phenylthio)thymine. J. Med. Chem. 1989, 32 (12), 2507-2509.
16. Baba, M.; Tanaka, H.; De Clercq, E.; Pauwels, R.; Balzarini, J.; Schols, D.; Nakashima, H.; Perno, C.F.; Walker, R.T.; Miyasaka, T. Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative. Biochem. Biophys. Res. Commun. 1989, 165 (3), 1375-1381.
17. Elion, G.B.; Furman, P.A.; Fyfe, J.A.; de Miranda, P.; Beauchamp, L.; Schaeffer, H.J. Selectivity of action of an antiherpetic agent, 9-(2-hydroxyethoxymethyl) guanine. Proc. Natl. Acad. Sci. U. S. A. 1977, 74 (12), 5716-5720.
18. Habgood, M.D.; Liu, Z.D.; Dehkordi, L.S.; Khodr, H.H.; Abbott, J.; Hider, R.C. Investigation into the correlation between the structure of hydroxypyridinones and blood-brain barrier permeability. Biochem. Pharmacol. 1999, 57 (11), 1305-1310.
19. Hider, R.C.; Taylor, P.D.; Walkinshaw, M.; Wang, J.L.; van der Helm, D. Crystal structure of 3-hydroxy-1,2-dimethyl-pyridin-4(1H)-one: an iron (III) chelator study. J. Chem. Res., Synop. 1990 (10), 316-317.
20. Charalambous, J.; Dodd, A.; McPartlin, M.; Matondo, S.O.C.; Pathirana, N.D.; Powell, H.R. Synthesis and x-ray crystal structure of tris(1,2-dimethyl-3-hydroxypyrid-4-onato)iron(III). Polyhedron 1988, 7 (21), 2235-2237.
21. Xiao, G.Y.; van der Helm, D.; Hider, R.C.; Rai, B.L. Molecular modeling studies of a ferric hexadentate 3-hydroxy-2(1H)-pyridinone complex and an analogue by molecular mechanics, molecular dynamics, and free energy perturbation simulations. J. Phys. Chem. 1996, 100 (6), 2345-2352.
22. Ledwidge, M.T.; Draper, S.M.; Wilcock, D.J.; Corrigan, O.I. Physicochemical characterization of diclofenac N-(2-hydroxyethyl)pyrrolidine: anhydrate and dihydrate crystalline forms. J. Pharm. Sci. 1996, 85 (1), 16-21.
23. Harris, D.C. Quantitative Chemical Analysis; W.H. Freeman and Company: New York, 1991; 523-524.
24. Kontoghiorghes, G.J. Iron mobilization from ferritin using α-oxohydroxy heteroaromatic chelators. Biochem. J. 1986, 233 (1), 299-302.
25. Porter, J.B.; Gyparaki, M.; Burke, L.C.; Huehns, E.R.; Sarpong, P.; Saez, V.; Hider, R.C. Iron mobilization from hepatocyte monolayer cultures by chelators: the importance of membrane permeability and the iron-binding constant. Blood 1988, 72 (5), 1497-1503.
26. Hider, R.C.; Porter, J.B.; Singh, S. The design of therapeutically useful iron chelator. In The Development of Iron Chelators for Clinical Use; Bergeron, R.J., Brittenham, G.M., Eds.; CRC: Boca Raton, 1994; 354-371.
27. 51Cr-labelled ethylenediaminetetra-acetate, L-rhamnose and polyethyleneglycol 400 [corrected] as probe markers for assessment in vivo of human intestinal permeability. Clin. Sci. 1986, 71 (1), 71-80.
28. Travis, S.; Menzies, I. Intestinal permeability: functional assessment and significance. Clin. Sci. 1992, 82 (5), 471-488.
29. Hider, R.C.; Choudhury, R.; Rai, B.L.; Dehkordi, L.S.; Singh, S. Design of orally active iron chelators. Acta Haematol. 1996, 95 (1), 6-12.
30. Niedballa, U.; Vorbrueggen, H. A general synthesis of pyrimidine nucleosides. Angew. Chem., Int. Ed. 1970, 9 (6), 461-462.